Information non disponible
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.Article de revue
Leukemia, 34 (2), p. 441-450, 2020, ISSN: 0887-6924.
Evaluation of eligibility and recruitment in breast cancer clinical trials.Article de revue
Breast, 23 (4), p. 385-92, 2014, ISSN: 0960-9776.
Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.Article de revue
Ann Pharmacother, 48 (4), p. 447-55, 2014, ISSN: 1060-0280.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.Article de revue
Blood, 121 (9), p. 1517-23, 2013, ISSN: 0006-4971.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.Article de revue
Lancet Oncol, 12 (11), p. 1013-22, 2011, ISSN: 1470-2045.
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.Article de revue
J Clin Oncol, 29 (25), p. 3396-401, 2011, ISSN: 0732-183X.